Table 1. Baseline Characteristics.
| Characteristic | No. (%) | |
|---|---|---|
| Dorzolamide-timolol (n = 27) | Placebo (n = 23) | |
| Age, mean (SD) [range], y | 79.7 (7.5) [65-94] | 77.5 (6.3) [68-87] |
| Male | 9 (33) | 7 (30) |
| Right eyes | 14 (52) | 10 (43) |
| Intravitreal anti-VEGF agent used | ||
| Aflibercept | 13 (48) | 14 (61) |
| Ranibizumab | 14 (52) | 9 (39) |
| Bevacizumab | NA | NA |
| Prior injections with same anti-VEGF, mean (SD) [range] | 20.0 (15.6) [4-58] | 21.1 (11.6) [4-51] |
| Current injection interval | ||
| Every 4 wk | 17 (63) | 12 (52) |
| Every 5 wk | 3 (11) | 8 (35) |
| Every 6 wk | 7 (26) | 3 (13) |
| Baseline VA, mean (SD) | ||
| logMAR | 0.370 (0.31) | 0.348 (0.19) |
| Approximate Snellen equivalent (letters) | 20/50 (67) | 20/50 (67) |
| Baseline IOP, mean (SD), mm Hg | 14.37 (2.9) | 14.22 (3.1) |
| Time between baseline and visit, mean (SD), d | ||
| Visit 1 | 32.41 (5.7) | 32.43 (4.9) |
| Visit 2 | 66.04 (11.3) | 66.17 (9.4) |
| Visit 3, mean (SD) [range], d | 98.65 (16.0) [84-126] | 100.70 (13.1) [84-126] |
| Baseline OCT measurements | ||
| Presence of fluid | ||
| Subretinal | 23 (85) | 19 (83) |
| Intraretinal | 13 (48) | 7 (30) |
| Presence of pigment epithelial detachment | 25 (93) | 21 (91) |
| Central subfield thickness at baseline, mean (SD), μm | 348.3 (75.5) | 321.3 (80.5) |
| Pigment epithelial detachment height, mean (SD), μm | 230.2 (116.4) | 178.9 (111.0) |
| Maximum subretinal fluid height, mean (SD), μm | 103.15 (68.5) | 90.0 (70.5) |
| Central subfoveal, mean (SD), μm | ||
| Fluid height | 48.3 (63.4) | 62.6 (97.1) |
| Thickness | 261.9 (108.0) | 229.9 (77.2) |
Abbreviations: IOP, intraocular pressure; VA, visual acuity; VEGF, vascular endothelial growth factor.